IL249234A0 - Osteoclast inhibitors for pain - Google Patents

Osteoclast inhibitors for pain

Info

Publication number
IL249234A0
IL249234A0 IL249234A IL24923416A IL249234A0 IL 249234 A0 IL249234 A0 IL 249234A0 IL 249234 A IL249234 A IL 249234A IL 24923416 A IL24923416 A IL 24923416A IL 249234 A0 IL249234 A0 IL 249234A0
Authority
IL
Israel
Prior art keywords
pain
osteoclast inhibitors
osteoclast
inhibitors
Prior art date
Application number
IL249234A
Other languages
Hebrew (he)
Inventor
Tabuteau Herriot
K M Dinkla Eric
Jones Graeme
Original Assignee
Antecip Bioventures Ii Llc
Tabuteau Herriot
K M Dinkla Eric
Jones Graeme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/288,241 external-priority patent/US8901161B1/en
Priority claimed from US14/288,720 external-priority patent/US8865757B1/en
Priority claimed from US14/288,713 external-priority patent/US8901162B1/en
Priority claimed from US14/310,811 external-priority patent/US8822436B1/en
Priority claimed from PCT/US2014/050427 external-priority patent/WO2015060924A1/en
Priority claimed from US14/457,659 external-priority patent/US20140349974A1/en
Priority claimed from US14/495,732 external-priority patent/US9127069B1/en
Priority claimed from US14/530,556 external-priority patent/US20150051175A1/en
Priority claimed from US14/536,526 external-priority patent/US20150057250A1/en
Priority claimed from US14/604,524 external-priority patent/US9211257B2/en
Priority claimed from US14/608,855 external-priority patent/US9079927B1/en
Priority claimed from US14/625,457 external-priority patent/US9427403B2/en
Priority claimed from US14/639,013 external-priority patent/US9289441B2/en
Priority claimed from PCT/US2015/032739 external-priority patent/WO2015184003A1/en
Application filed by Antecip Bioventures Ii Llc, Tabuteau Herriot, K M Dinkla Eric, Jones Graeme filed Critical Antecip Bioventures Ii Llc
Publication of IL249234A0 publication Critical patent/IL249234A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL249234A 2014-05-27 2016-11-27 Osteoclast inhibitors for pain IL249234A0 (en)

Applications Claiming Priority (28)

Application Number Priority Date Filing Date Title
US14/288,241 US8901161B1 (en) 2014-05-27 2014-05-27 Therapeutic compositions comprising imidazole and imidazolium compounds
US14/288,720 US8865757B1 (en) 2014-05-28 2014-05-28 Therapeutic compositions comprising imidazole and imidazolium compounds
US14/288,713 US8901162B1 (en) 2014-01-30 2014-05-28 Substituted imidazolium compounds for treating disease
US14/288,716 US8835650B1 (en) 2014-01-30 2014-05-28 Substituted imidazolium compounds for treating disease
US201462012112P 2014-06-13 2014-06-13
US14/310,811 US8822436B1 (en) 2012-05-14 2014-06-20 Compositions for oral administration of zoledronic acid or related compounds for treating disease
US14/336,642 US20140329773A1 (en) 2012-05-14 2014-07-21 Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease
US14/446,184 US9006279B1 (en) 2014-01-30 2014-07-29 Substituted imidazolium compounds for treating disease
PCT/US2014/050427 WO2015060924A1 (en) 2013-10-25 2014-08-08 Compositions for oral administration of zoledronic acid or related compounds for treating disease
US14/457,659 US20140349974A1 (en) 2014-08-12 2014-08-12 Zoledronic acid dosage forms for the treatment of pain
US14/481,097 US8962599B1 (en) 2014-05-27 2014-09-09 Therapeutic compositions comprising imidazole and imidazolium compounds
US201462053619P 2014-09-22 2014-09-22
US14/495,732 US9127069B1 (en) 2014-06-11 2014-09-24 Compositions comprising rank/rankl antagonists and related compounds for treating pain
US14/530,556 US20150051175A1 (en) 2012-05-14 2014-10-31 Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain
US14/536,526 US20150057250A1 (en) 2012-05-14 2014-11-07 Inhibitors of osteoclast activity for treating arthritis
US14/538,709 US9290575B2 (en) 2014-06-11 2014-11-11 Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
US14/540,333 US9216168B1 (en) 2014-05-27 2014-11-13 Therapeutic compositions comprising imidazole and imidazolium compounds
US14/604,524 US9211257B2 (en) 2012-05-14 2015-01-23 Osteoclast inhibitors for knee conditions
US14/605,822 US9216153B2 (en) 2012-05-14 2015-01-26 Osteoclast inhibitors for knee conditions
US14/607,947 US9289384B2 (en) 2012-05-14 2015-01-28 Osteoclast inhibitors for knee conditions
US14/607,985 US9289385B2 (en) 2012-05-14 2015-01-28 Osteoclast inhibitors for knee conditions
US14/608,855 US9079927B1 (en) 2014-05-27 2015-01-29 Substituted imidazolium compounds for treating disease
US14/625,457 US9427403B2 (en) 2012-05-14 2015-02-18 Methods for the safe administration of imidazole or imidazolium compounds
US201562127214P 2015-03-02 2015-03-02
US14/635,857 US9283239B2 (en) 2012-05-14 2015-03-02 Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US14/639,013 US9289441B2 (en) 2014-08-08 2015-03-04 Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US14/686,551 US9408860B2 (en) 2012-05-14 2015-04-14 Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
PCT/US2015/032739 WO2015184003A1 (en) 2014-05-27 2015-05-27 Osteoclast inhibitors for pain

Publications (1)

Publication Number Publication Date
IL249234A0 true IL249234A0 (en) 2017-02-28

Family

ID=57681122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL249234A IL249234A0 (en) 2014-05-27 2016-11-27 Osteoclast inhibitors for pain

Country Status (8)

Country Link
EP (1) EP3148534A4 (en)
JP (2) JP6457555B2 (en)
KR (4) KR20210149861A (en)
AU (1) AU2015267046C1 (en)
IL (1) IL249234A0 (en)
MX (1) MX2016015552A (en)
NZ (1) NZ726690A (en)
SG (3) SG10201706414SA (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
EP2593122A1 (en) * 2010-07-16 2013-05-22 Merck Patent GmbH Peptide for use in the treatment of breast cancer and/or bone metastases
US8802658B2 (en) * 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
CA2987470A1 (en) * 2012-05-14 2013-11-21 Antecip Bioventures Ii Llc Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions

Also Published As

Publication number Publication date
EP3148534A4 (en) 2018-01-24
KR20210149861A (en) 2021-12-09
SG10201706414SA (en) 2017-09-28
KR101975645B1 (en) 2019-05-07
SG11201609767PA (en) 2016-12-29
KR20190010728A (en) 2019-01-30
AU2015267046B2 (en) 2018-07-19
SG10201906609UA (en) 2019-08-27
KR20170005872A (en) 2017-01-16
JP2017516788A (en) 2017-06-22
KR20210038700A (en) 2021-04-07
AU2015267046A1 (en) 2016-12-15
KR102409599B1 (en) 2022-06-22
AU2015267046C1 (en) 2018-10-25
EP3148534A1 (en) 2017-04-05
MX2016015552A (en) 2018-01-12
JP2019069979A (en) 2019-05-09
NZ726690A (en) 2018-03-23
JP6457555B2 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
IL287113A (en) Smyd inhibitors
HK1244792B (en) Necrosis inhibitors
IL251584B (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL246902A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
HK1244480A1 (en) Necrosis inhibitors
ZA201606174B (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
HRP20181441T1 (en) Aldosterone synthase inhibitors
GB201501004D0 (en) Inhibitors
AP2017009829A0 (en) Aldosterone synthase inhibitors
GB201400299D0 (en) Corrosion inhibitors
EP3628374C0 (en) Bcl-3 inhibitors
GB201520949D0 (en) Inhibitors
IL249234A0 (en) Osteoclast inhibitors for pain
GB201418154D0 (en) Inhibitors
GB201400300D0 (en) Corrosion inhibitors